

**IN THE UNITED STATES PATENT
AND TRADEMARK OFFICE**

Serial No. : 10/054,300
Applicant(s): Takeshi IMANISHI et al.
Filed : January 22, 2002
For : NOVEL BICYCLONUCLEOSIDE
ANALOGUES
Art Unit : 1623
Examiner : Travis C. McIntosh III
Docket No. : 01834CIP/HG
Customer No.: 01933
Confirm No. : 5360

**STATEMENT OF ACCURACY OF TRANSLATION
(37 C.F.R. 1.55 & 1.68)**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

MAIL STOP AMENDMENT

S I R :

The undersigned translator, having an office at

states that:

- (1) I am fully conversant both with the Japanese and English languages.
- (2) I have carefully compared the attached English language translation of Japanese Patent Application Number Hei 11-207170, filed July 22, 1999 with the original Japanese

language patent application.

- (3) The translation is, to the best of my knowledge and belief, an accurate translation from the original into the English language.

Date: August 18, 2006 Takamitsu Yoneda

Takamitsu YONEDA

(Type name of translator above)

English Translation
of Certified Copy

PATENT OFFICE
JAPANESE GOVERNMENT

This is to certify that the annexed is a true copy of the following application
as filed with this Office.

Date of Application : July 22, 1999

Application Number : Patent Application No. Hei 11-207170

Applicant : SANKYO COMPANY, LIMITED

Date : June 9, 2000

Commissioner, Takahiko Kondo
Patent Office

Official Seal

Certificate Serial No.

11-207170

Name of Document	Patent Application
Docket Number	99105SY
Address To :	Commissioner, Patent Office
International Patent Classification	C07H 19/06
Inventor	
Address or Domicile Name	2-18, Chiyogaoka 2-chome, Nara-shi, Nara, Japan Takeshi Imanishi
Inventor	
Address or Domicile Name	4-2034, Hiyoshidai, Takatsuki-shi, Osaka, Japan Satoshi Obika
Patent Applicant	
Identification Number	000001856
Name	SANKYO COMPANY, LIMITED
Agent	
Identification Number	100081400
Patent Attorney Name	Akio Ohno
Appointed Agent	
Identification Number	100092716
Patent Attorney Name	Yasuo Nakada
Appointed Agent	
Identification Number	100096666
Patent Attorney Name	Yoshinobu Murofushi
Indication of Official Fee	
Prepayment Register Number	010216
Amount to be paid	21,000 yen

11-207170

List of Materials to be submitted

Name of Material	Specification	1
------------------	---------------	---

Name of Material	Abstract	1
------------------	----------	---

Number of General Power of Attorney	9704937
-------------------------------------	---------

Number of General Power of Attorney	9704935
-------------------------------------	---------

Number of General Power of Attorney	9704936
-------------------------------------	---------


Necessity for Proof	Yes
---------------------	-----

[Document name] Specification

[Name of invention] Novel bicyclonucleoside analogues

[Claims]

1. A compound of general formula (1) or a pharmaceutically acceptable salt thereof,



[wherein, R¹ is the same or different, and each represents a hydrogen atom or a protecting group for a hydroxy group;

R² represents an azido group or an amino group which is optionally protected with a protecting group;

B represents a purin-9-yl group or a pyrimidin-1-yl group each of which is optionally substituted with 1 or more substituents selected from the following α group].

(α Group)

a halogen atom,

an alkyl group having from 1 to 6 carbon atoms

a hydroxy group which is optionally protected with a protecting group,

a mercapto group which is optionally protected with a protecting group,

an amino group which is optionally protected with a protecting group,

an alkoxy group having from 1 to 6 carbon atoms,

an alkylthio group having from 1 to 6 carbon atoms, and

a mono- or di-alkylamino group each of which is substituted by alkyl group(s) having from 1 to 6 carbon atoms].

2. A compound or a pharmaceutically acceptable salt thereof according to Claim 1, wherein R¹ represents a hydrogen atom, an aliphatic acyl group, an aromatic acyl group, a silyl group, a methyl

group substituted by 1 to 3 aryl groups, or a methyl group substituted by 1 to 3 aryl groups wherein the aryl rings are substituted by a lower-alkyl, a lower-alkoxy, a halogen or a cyano group.

3. A compound or a pharmaceutically acceptable salt thereof according to Claim 1, wherein R^1 represents a hydrogen atom, a silyl group, a methyl group substituted by 1 to 3 aryl groups, or a methyl group substituted by 1 to 3 aryl groups wherein the aryl rings are substituted by a lower-alkyl, a lower-alkoxy, a halogen or a cyano group.

4. A compound or a pharmaceutically acceptable salt thereof according to Claim 1, wherein R^1 represents a hydrogen atom, a trimethylsilyl group, a t-butyldimethylsilyl group, a t-butyldiphenylsilyl group, a benzyl group, a triphenylmethyl group, a 4-methoxybenzyl group, a 4-methoxyphenyldiphenylmethyl group, a 4,4'-dimethoxytriphenylmethyl group, or a 4,4',4''-trimethoxytriphenylmethyl group.

5. A compound or a pharmaceutically acceptable salt thereof according to Claims 1 to 4, wherein R^2 represents an azido group or an amino group which is optionally protected with an aliphatic acyl group or an aromatic acyl group.

6. A compound or a pharmaceutically acceptable salt thereof according to Claims 1 to 4, wherein R^2 represents an azido group or an amino group which is optionally protected with an acetyl group, a trifluoroacetyl group or a benzoyl group.

7. A compound or a pharmaceutically acceptable salt thereof according to Claims 1 to 4, wherein R^2 represents an azido group or an amino group.

8. A compound or a pharmaceutically acceptable salt thereof according to Claims 1 to 7, wherein B represents a 6-aminopurin-9-yl

(*i.e.*, adeninyl) in which the amino group is optionally protected with a protecting group, a 2,6-diaminopurin-9-yl in which the amino group is optionally protected with a protecting group, a 2-amino-6-chloropurin-9-yl in which the amino group is optionally protected with a protecting group, a 2-amino-6-fluoropurin-9-yl in which the amino group is optionally protected with a protecting group, a 2-amino-6-bromopurin-9-yl in which the amino group is optionally protected with a protecting group, a 2-amino-6-hydroxypurin-9-yl (*i.e.*, guaninyl) in which the amino group is optionally protected with a protecting group, a 6-amino-2-methoxypurin-9-yl in which the amino group is optionally protected with a protecting group, a 6-amino-2-chloropurin-9-yl in which the amino group is optionally protected with a protecting group, a 6-amino-2-fluoropurin-9-yl in which the amino group is optionally protected with a protecting group, a 2,6-dimethoxypurin-9-yl, a 2,6-dichloropurin-9-yl, a 6-mercaptopurin-9-yl in which the mercapto group is optionally protected with a protecting group, a 2-oxo-4-amino-1,2-dihydropyrimidin-1-yl (*i.e.*, cytosinyl) in which the amino group is optionally protected with a protecting group, a 4-amino-2-oxo-5-fluoro-1,2-dihydropyrimidin-1-yl in which the amino group is optionally protected with a protecting group, a 4-amino-2-oxo-5-chloro-1,2-dihydropyrimidin-1-yl in which the amino group is optionally protected with a protecting group, a 2-oxo-4-methoxy-1,2-dihydropyrimidin-1-yl, a 2-oxo-4-mercapto-1,2-dihydropyrimidin-1-yl in which the mercapto group is optionally protected with a protecting group, a 2,4-dihydroxypyrimidin-1-yl (*i.e.*, uracilyl), a 2,4-dihydroxy-5-methylpyrimidin-1-yl (*i.e.*, thyminyl), or a 4-amino-5-methyl-2-oxo-1,2-dihydropyrimidin-1-yl in which the amino group is optionally protected with a protecting group.

9. A compound or a pharmaceutically acceptable salt thereof according to Claims 1 to 7, wherein B represents a 6-benzoylamino-2-aminopurin-9-yl, an adeninyl, a 2-benzoylamino-6-hydroxypurin-9-yl, a guaninyl, a 2-oxo-4-benzoylamino-1,2-dihydropyrimidin-1-yl, a cytosinyl, a uracilyl or a thyminyl.

10. A compound according to Claim 1, which represents the following compound: 3'-amino-3'-deoxy-2'-O,4'-C-methylene-5-methyluridine, 3'-azido-3'-deoxy-2'-O,4'-C-methylene-5-methyluridine, or 3'-azido-5'-O-tert-butyldiphenylsilyl-3'-deoxy-2'-O,4'-C-methylene-5-methyluridine.

[Detailed description of the invention]

[0001]

[Technical field]

This invention relates to novel modified oligonucleoside analogues which exhibit anti-AIDS activity and relates to novel modified nucleoside analogues which are useful for synthesis of non-natural oligonucleotide analogues which exhibit excellent anti-sense or anti-gene activity and in vivo stability.

[0002]

[Background art]

Oligonucleotides having excellent anti-sense or anti-gene activities and in vivo stability have been expected to be useful medicaments.

[0003]

However, it is well known that natural oligonucleotides are rapidly decomposed by various nucleases in the blood or cells.

[0004]

To solve these problems, numerous non-natural modified oligonucleotide analogues have been synthesized, and it has been tried to develop them as medicaments. For example, oligonucleotides wherein the oxygen atom binding to the phosphorus atom of the phosphodiester linkage is substituted by a sulfur atom, a methyl group, or a boron atom, are known. Further, oligonucleotides whose sugar and/or base moieties are chemically modified are also known.

More concretely, ISIS Co. has developed a thioate oligonucleotide, ISIS2922, as a therapeutic agent for retinitis infected by human cytomegalovirus and this has been sold as Vitravene (trade name) in the United States.

[0005]


Any non-natural modified oligonucleotides described above, however, have not been fully satisfactory due to their insufficient potency of anti-sense or anti-gene activity, (*i.e.*, ability to form

complementary strands with mRNA or DNA) and stability to various nucleases, and due to side effects caused by non-selective binding to various proteins in vivo. Thus it has been desired to develop non-natural modified oligonucleotide analogues having more potent anti-sense or anti-gene activities, in vivo stability, and fewer side effects.

[0006]

Compounds having a dioxabicyclo[2,2,1]heptane moiety which is related to that of the present invention and which is shown below are described in WO98/39352. These compounds differ from the compounds of the present invention in the substituent at the 3' position of ribose.

[0007]



wherein B⁰ represents pyrimidine or purine nucleic acid base or their analogues, X and Y are the same or different and each represents a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, an aralkyl group, an aryl group, an acyl group or a silyl group.

[0008]

[Subject of the invention]

An objective of the present invention is to provide novel modified nucleoside analogues having anti-AIDS activity and to provide novel modified nucleoside analogues which are useful for synthesis of non-natural modified oligonucleotides which exhibit excellent anti-sense or anti-gene activity, in vivo stability and fewer side effects.

[0009]


[Solution of the subject]

The present inventors have performed painstaking research to complete these objectives, and found that novel bicyclonucleoside analogues having a 2'-O,4'-C-methylene moiety are useful anti-

AIDS agents and are important intermediate compounds to synthesize said modified oligonucleotides. Thus the present inventors have completed the present invention.

[0010]

The novel bicyclonucleoside analogues are the compounds represented by the general formula (1) or their pharmaceutically acceptable salts,



(1)

[0011]

[wherein, R¹ is the same or different, and each represents a hydrogen atom or a protecting group for a hydroxy group;

R² represents an azido group or an amino group which is optionally protected with a protecting group;

B represents a purin-9-yl group or a pyrimidin-1-yl group each of which is optionally substituted with 1 or more substituents selected from the following α group].

(α Group)

a halogen atom,

an alkyl group having from 1 to 6 carbon atoms

a hydroxy group which is optionally protected with a protecting group,

a mercapto group which is optionally protected with a protecting group,

an amino group which is optionally protected with a protecting group,

an alkoxy group having from 1 to 6 carbon atoms,

an alkylthio group having from 1 to 6 carbon atoms, and

a mono- or di-alkylamino group each of which is substituted by alkyl group(s) having from 1 to 6 carbon atoms].

[0012]

Preferred compounds of the present invention are:

2. a compound wherein R^1 represents a hydrogen atom, an aliphatic acyl group, an aromatic acyl group, a silyl group, a methyl group substituted by 1 to 3 aryl groups, or a methyl group substituted by 1 to 3 aryl groups wherein the aryl rings are substituted by a lower-alkyl, a lower-alkoxy, a halogen or a cyano group,
3. a compound wherein R^1 represents a hydrogen atom, a silyl group, a methyl group substituted by 1 to 3 aryl groups, or a methyl group substituted by 1 to 3 aryl groups wherein the aryl rings are substituted by a lower-alkyl, a lower-alkoxy, a halogen or a cyano group,
4. a compound wherein R^1 represents a hydrogen atom, a trimethylsilyl group, a t-butyldimethylsilyl group, a t-butyldiphenylsilyl group, a benzyl group, a triphenylmethyl group, a 4-methoxybenzyl group, a 4-methoxyphenyldiphenylmethyl group, a 4,4'-dimethoxytriphenylmethyl group, or a 4,4',4''-trimethoxytriphenylmethyl group,
5. a compound wherein R^2 represents an azido group or an amino group which is optionally protected with an aliphatic acyl group or an aromatic acyl group,
6. a compound wherein R^2 represents an azido group or an amino group which is optionally protected with an acetyl group, a trifluoroacetyl group or a benzoyl group,
7. a compound wherein R^2 represents an azido group or an amino group,
8. a compound wherein B represents a 6-aminopurin-9-yl (*i.e.*, adeninyl) in which the amino group is optionally protected with a protecting group, a 2,6-diaminopurin-9-yl in which the amino group(s) is optionally protected with a protecting group, a 2-amino-6-chloropurin-9-yl in which the amino group is optionally protected with a protecting group, a 2-amino-6-fluoropurin-9-yl

in which the amino group is optionally protected with a protecting group, a 2-amino-6-bromopurin-9-yl in which the amino group is optionally protected with a protecting group, a 2-amino-6-hydroxypurin-9-yl (*i.e.*, guaninyl) in which the amino group is optionally protected with a protecting group, a 6-amino-2-methoxypurin-9-yl in which the amino group is optionally protected with a protecting group, a 6-amino-2-chloropurin-9-yl in which the amino group is optionally protected with a protecting group, a 6-amino-2-fluoropurin-9-yl in which the amino group is optionally protected with a protecting group, a 2,6-dimethoxypurin-9-yl, a 2,6-dichloropurin-9-yl, a 6-mercaptopurin-9-yl in which the mercapto group is optionally protected with a protecting group, a 2-oxo-4-amino-1,2-dihydropyrimidin-1-yl (*i.e.*, cytosinyl) in which the amino group is optionally protected with a protecting group, a 4-amino-2-oxo-5-fluoro-1,2-dihydropyrimidin-1-yl in which the amino group is optionally protected with a protecting group, a 4-amino-2-oxo-5-chloro-1,2-dihydropyrimidin-1-yl in which the amino group is optionally protected with a protecting group, a 2-oxo-4-methoxy-1,2-dihydropyrimidin-1-yl, a 2-oxo-4-mercapto-1,2-dihydropyrimidin-1-yl in which the mercapto group is optionally protected with a protecting group, a 2,4-dihydroxypyrimidin-1-yl (*i.e.*, uracilyl), a 2,4-dihydroxy-5-methylpyrimidin-1-yl (*i.e.*, thyminyl), or a 4-amino-5-methyl-2-oxo-1,2-dihydropyrimidin-1-yl in which the amino group is optionally protected with a protecting group,

9. a compound wherein B represents a 6-benzoylamino-9-yl, an adeninyl, a 2-benzoylamino-6-hydroxypurin-9-yl, a guaninyl, a 2-oxo-4-benzoylamino-1,2-dihydropyrimidin-1-yl, a cytosinyl, an uracilyl or a thyminyl.

[0013]

10. More preferred compounds are:

3'-amino-3'-deoxy-2'-O,4'-C-methylene-5-methyluridine, 3'-azido-3'-deoxy-2'-O,4'-C-methylene-5-methyluridine, or 3'-azido-5'-O-tert-butyldiphenylsilyl-3'-deoxy-2'-O,4'-C-methylene-5-methyluridine.

[0014]

Examples of the "protecting group for a hydroxy group" in the definition of above R^1 are:

"An aliphatic acyl group", for example, an alkylcarbonyl group such as formyl, acetyl, propionyl, butyryl, isobutyryl, pentanoyl, pivaloyl, valeryl, isovaleryl, octanoyl, decanoyl, 8-methylnonanoyl, 3-ethyloctanoyl, 3,7-dimethyloctanoyl, undecanoyl, tridecanoyl, hexadecanoyl, 14-methylpentadecanoyl, 13,13-dimethyltetradecanoyl, 1-methylheptadecanoyl, nonadecanoyl, eicosanoyl and henicosanoyl, a carboxylated alkylcarbonyl group such as succinoyl, glutaroyl, and adipoyl, a halogeno-lower-alkylcarbonyl group such as chloroacetyl, dichloroacetyl, trichloroacetyl, and trifluoroacetyl, a lower-alkoxy-lower-alkylcarbonyl group such as methoxyacetyl, and an unsaturated alkylcarbonyl group such as (E)-2-methyl-2-butenoyl;

"An aromatic acyl group", for example, an arylcarbonyl group such as benzoyl, α -naphthoyl, and β -naphthoyl, a halogenoarylcarbonyl group such as 2-bromobenzoyl, 4-chlorobenzoyl, a lower-alkylated-arylcarbonyl group such as 2,4,6-trimethylbenzoyl, and 4-toluoyl, a lower-alkoxylated arylcarbonyl group such as 4-anisoyl, a carboxylated arylcarbonyl group such as 2-carboxybenzoyl, 3-carboxybenzoyl, and 4-carboxybenzoyl, a nitrated arylcarbonyl group such as 4-nitrobenzoyl, and 2-nitrobenzoyl; a lower-alkoxycarbonylated arylcarbonyl group such as 2-(methoxycarbonyl)benzoyl, an arylated arylcarbonyl group such as 4-phenylbenzoyl;

"A tetrahydropyranyl or tetrahydrothiopyranyl group" such as tetrahydropyran-2-yl, 3-bromotetrahydropyran-2-yl, 4-methoxytetrahydropyran-4-yl, tetrahydrothiopyran-2-yl, and 4-methoxytetrahydrothiopyran-4-yl;

"A tetrahydrofuranyl or a tetrahydrothiofuranyl group" such as tetrahydrofuran-2-yl, and tetrahydrothiofuran-2-yl;

"Silyl groups", for example, a tri-lower-alkyl silyl group such as trimethylsilyl, triethylsilyl, isopropyl dimethylsilyl, t-butyl dimethylsilyl, methyl diisopropylsilyl, methyl di-t-butylsilyl, and triisopropylsilyl, a tri-lower-alkyl silyl group substituted by 1 or 2 aryl groups such as diphenylmethylsilyl,

t-butyldiphenylsilyl, diphenylisopropylsilyl, and phenyldiisopropylsilyl;

"A lower-alkoxymethyl group" such as methoxymethyl, 1,1-dimethyl-1-methoxymethyl, ethoxymethyl, propoxymethyl, isopropoxymethyl, butoxymethyl, and t-butoxymethyl;

"A lower-alkoxylated lower-alkoxymethyl group" such as 2-methoxyethoxymethyl;

"A halogeno-lower-alkoxymethyl group" such as 2,2,2-trichloroethoxymethyl, and bis(2-chloroethoxy)methyl;

"A lower-alkoxylated ethyl group" such as 1-ethoxyethyl, and 1-(isopropoxy)ethyl;

"A halogenated ethyl group" such as 2,2,2-trichloroethyl;

"A methyl group substituted by 1 to 3 aryl groups" such as benzyl, α -naphthylmethyl, β -naphthylmethyl, diphenylmethyl, triphenylmethyl, α -naphthyldiphenylmethyl, and 9-anthrylmethyl;

"A methyl group substituted by 1 to 3 aryl groups wherein the aryl ring is substituted by lower-alkyl, lower-alkoxy, halogen or cyano groups" such as 4-methylbenzyl, 2,4,6-trimethylbenzyl, 3,4,5-trimethylbenzyl, 4-methoxybenzyl, 4-methoxyphenyldiphenylmethyl, 4,4'-dimethoxytriphenylmethyl, 4,4',4''-trimethoxytriphenylmethyl, 2-nitrobenzyl, 4-nitrobenzyl, 4-chlorobenzyl, 4-bromobenzyl, and 4-cyanobenzyl;

"A lower-alkoxycarbonyl group" such as methoxycarbonyl, ethoxycarbonyl, t-butoxycarbonyl, and isobutoxycarbonyl;

"A lower-alkoxycarbonyl group substituted by a halogen atom or a tri-lower-alkylsilyl group" such as 2,2,2-trichloroethoxycarbonyl, and 2-trimethylsilylethoxycarbonyl;

"An alkenyloxycarbonyl group" such as vinyloxycarbonyl, and allyloxycarbonyl;

"An aralkyloxycarbonyl group wherein the aryl ring may be substituted by 1 or 2 lower-alkoxy or nitro groups" such as benzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 3,4-dimethoxydibenzyloxycarbonyl, 2-nitrobenzyloxycarbonyl, and 4-nitrobenzyloxycarbonyl.

Preferred protecting groups are an aliphatic acyl group, an aromatic acyl group, a silyl group, a methyl group substituted by

1 to 3 aryl groups, a methyl group substituted by 1 to 3 aryl groups wherein the aryl ring is substituted by a lower-alkyl, a lower-alkoxy, a halogen or a cyano group. More preferred protecting groups are a silyl group, a methyl group substituted by 1 to 3 aryl groups, a methyl group substituted by 1 to 3 aryl groups wherein the aryl ring is substituted by a lower-alkyl, a lower-alkoxy, a halogen or a cyano group. Most preferred protecting groups are a trimethylsilyl group, a t-butyldimethylsilyl group, a t-butyldiphenylsilyl group, a benzyl group, a triphenylmethyl group, a 4-methoxybenzyl group, a 4-methoxyphenyldiphenylmethyl group, a 4,4'-dimethoxytriphenylmethyl, or a 4,4',4''-trimethoxytriphenylmethyl group.

[0015]

"An amino group which is optionally protected with a protecting group" described in the definition of R^2 above are an amino group which is optionally protected with 1 or 2 protecting groups which are the same or different. These protecting groups are,

"An aliphatic acyl group" for example, an alkylcarbonyl group such as formyl, acetyl, propionyl, butyryl, isobutyryl, pentanoyl, pivaloyl, valeryl, isovaleryl, octanoyl, decanoyl, 8-methylnonanoyl, 3-ethyloctanoyl, 3,7-dimethyloctanoyl, undecanoyl, tridecanoyl, hexadecanoyl, 14-methylpentadecanoyl, 13,13-dimethyltetradecanoyl, 1-methylheptadecanoyl, nonadecanoyl, eicosanoyl and heneicosanoyl; a carboxylated-alkylcarbonyl group such as succinoyl, glutaroyl, and adipoyl; a halogeno-lower-alkylcarbonyl group such as chloroacetyl, dichloroacetyl, trichloroacetyl, and trifluoroacetyl; a lower-alkoxy-lower-alkylcarbonyl group such as methoxyacetyl; an unsaturated-alkylcarbonyl group such as (E)-2-methyl-2-butenoyl.

"An aromatic acyl group", for example, an arylcarbonyl group such as benzoyl, α -naphthoyl, and β -naphthoyl; a halogeno-arylcarbonyl group such as 2-bromobenzoyl, and 4-chlorobenzoyl; a lower-alkylated-arylcarbonyl group such as 2,4,6-trimethylbenzoyl, and 4-toluoyl; a lower-alkoxylated-arylcarbonyl group such as 4-anisoyl; a carboxylated-arylcarbonyl group such as 2-

carboxybenzoyl, 3-carboxybenzoyl, and 4-carboxybenzoyl; a nitrated-arylcarbonyl group such as 4-nitrobenzoyl, and 2-nitrobenzoyl; a lower-alkoxycarbonylated-arylcarbonyl group such as 2-(methoxycarbonyl)benzoyl, an arylated-arylcarbonyl group such as 4-phenylbenzoyl.

"A lower-alkoxycarbonyl group" such as methoxycarbonyl, ethoxycarbonyl, t-butoxycarbonyl, and isobutoxycarbonyl.

"A lower-alkoxycarbonyl group substituted by a halogen or a tri-lower-alkylsilyl group" such as 2,2,2-trichloroethoxycarbonyl, and 2-trimethylsilylethoxycarbonyl.

"An alkenyloxycarbonyl group" such as vinyloxycarbonyl, and allyloxycarbonyl.

"An aralkyloxycarbonyl group wherein the aryl ring may be substituted by 1 or 2 lower-alkoxy or nitro groups" such as benzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 3,4-dimethoxybenzyloxycarbonyl, 2-nitrobenzyloxycarbonyl and 4-nitrobenzyloxycarbonyl.

Among these, preferred groups are "an aliphatic acyl group" or "an aromatic acyl group".

More preferred groups are an acetyl group, a trifluoroacetyl group or a benzoyl group.

[0016]

"A halogen atom" described in the above definition of the α group is a fluorine, chlorine, bromine, or iodine atom, and preferred atoms are fluorine or chlorine atoms.

[0017]

"An alkyl group having from 1 to 6 carbon atoms" described in the above definition of α group is, for example, a straight or branched chain alkyl group having from 1 to 6 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, s-butyl, isobutyl, tert-butyl, pentyl and hexyl. Preferred groups are methyl or ethyl groups.

[0018]

A protecting group of "a hydroxy group which is optionally protected with a protecting group" described in the above definition of α group is a similar group to that described above

in the "protecting group for a hydroxy group" in the above definition of R^1 . Preferred groups are "an aliphatic acyl group" and "an aromatic acyl group", and the most preferred group is a benzoyl group.

[0019]

A protecting group of "a mercapto group which is optionally protected with a protecting group" described in the above definitions of α group is, for example, "a disulfide-forming group", for example an alkylthio group such as methylthio, ethylthio and tert-butylthio, and an arylthio group such as benzylthio, in addition to the groups described in the "protecting group for a hydroxy group" in the definition of R^1 .

Among these, preferred groups are "an aliphatic acyl group" or "an aromatic acyl group", and the most preferred group is a benzoyl group.

[0020]

A protecting group of the "amino group which is optionally protected with a protecting group" described in the above definitions of α group is a similar group to those described in the "protecting group for an amino group", which has been already described in the definition of R^2 . Preferred groups are "an aliphatic acyl group" or "an aromatic acyl group", and the most preferred group is a benzoyl group.

[0021]

"An alkoxy group having from 1 to 6 carbon atoms" described in the above definitions of α group is, for example, a straight or branched chain alkoxy group having from 1 to 6 carbon atoms, such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, s-butoxy, tert-butoxy, pentyloxy, and hexyloxy. Preferred groups are methoxy or ethoxy groups.

[0022]

"An alkylthio group having from 1 to 6 carbon atoms" described in the above definitions α group is, for example, a methylthio, ethylthio, propylthio, isopropylthio, butylthio, isobutylthio, s-butylthio, tert-butylthio, pentylthio or hexylthio group. Preferred groups are methylthio or ethylthio groups.

[0023]

"A mono- or di-alkylamino group each of which is substituted by alkyl group(s) having from 1 to 6 carbon atoms" described in the above definitions of α group is, for example, a methylamino, ethylamino, propylamino, isopropylamino, butylamino, isobutylamino, s-butylamino, tert-butylamino, pentylamino, hexylamino, dimethylamino, diethylamino, dipropylamino, diisopropylamino, dibutylamino, diisobutylamino, di(s-butyl)amino, di(tert-butyl)amino, dipentylamino, or dihexylamino group. Preferred groups are methylamino, ethylamino, dimethylamino or diethylamino groups.

[0024]

"Pharmaceutically acceptable salts thereof" described above indicates the salts of the compounds (1) of this invention. Among these salts, preferred salts are, for example, inorganic acid salts such as hydrohalogenic acid salts, e.g., hydrofluoric acid salts, hydrochloric acid salts, hydrobromic acid salts and hydroiodic acid salts; nitric acid salts, perchloric acid salts, sulfuric acid salts and phosphoric acid salts; organic acid salts such as lower alkanesulfonic acid salts, e.g., methanesulfonic acid salts, trifluoromethanesulfonic acid salts and ethanesulfonic acid salts; arylsulfonic acid salts, e.g., benzenesulfonic acid salts and p-toluenesulfonic acid salts; acetic acid salts, malic acid salts, fumaric acid salts, succinic acid salts, citric acid salts, tartaric acid salts, oxalic acid salts and maleic acid salts; and amino acid salts such as glycine salts, lysine salts, arginine salts, ornithine salts, glutamic acid salts and aspartic acid salts.

[0025]

The compounds (1) of this invention absorb or adsorb water to form hydrates when they are left in atmosphere. These salts are included in the present invention.

[0026]

The compounds (1) of the present invention absorb certain solvents to form solvates. These salts are included in the present invention.

[0027]

Some typical examples of compound (1) of the present invention


can be exemplified by Tables 1 and 2.

[0028]

Abbreviations used in Table 1 and Table 2 are as follows;
Bn: a benzyl group, Bz: a benzoyl group, Me: a methyl group, PMBn: a p-methoxybenzyl group, MMTr: a 4-methoxytriphenylmethyl group, DMTr: a 4,4'-dimethoxytriphenylmethyl group, TMTr: a 4,4'4''-trimethoxytriphenylmethyl group, TMS: a trimethylsilyl group, TBDMS: a tert-butyldimethylsilyl group, TBDPS: a tert-butyldiphenylsilyl group.

[0029]

Table 1.



(I')

[0030]


Exemplification Compound number.	R ¹	R ²	R ³	R ⁴
1-1	H	NH ₂	H	H
1-2	H	NH ₂	H	OH
1-3	H	NH ₂	H	SH
1-4	H	NH ₂	H	NH ₂
1-5	H	NH ₂	H	OMe
1-6	H	NH ₂	F	H
1-7	H	NH ₂	F	NH ₂
1-8	H	NH ₂	Cl	H
1-9	H	NH ₂	Cl	NH ₂
1-10	H	NH ₂	Cl	Cl
1-11	H	NH ₂	Br	H
1-12	H	NH ₂	Br	NH ₂
1-13	H	NH ₂	OH	H
1-14	H	NH ₂	OH	OH
1-15	H	NH ₂	OH	NH ₂
1-16	H	NH ₂	OMe	OMe
1-17	H	NH ₂	OMe	NH ₂
1-18	H	NH ₂	NH ₂	H
1-19	H	NH ₂	NH ₂	F

1-20	H	NH ₂	NH ₂	Cl
1-21	H	NH ₂	NH ₂	Br
1-22	H	NH ₂	NH ₂	OH
1-23	H	NH ₂	NH ₂	NH ₂
1-24	H	NH ₂	NH ₂	OMe
1-25	H	N ₃	H	H
1-26	H	N ₃	H	OH
1-27	H	N ₃	H	SH
1-28	H	N ₃	H	NH ₂
1-29	H	N ₃	H	OMe
1-30	H	N ₃	F	H
1-31	H	N ₃	F	NH ₂
1-32	H	N ₃	Cl	H
1-33	H	N ₃	Cl	NH ₂
1-34	H	N ₃	Cl	Cl
1-35	H	N ₃	Br	H
1-36	H	N ₃	Br	NH ₂
1-37	H	N ₃	OH	H
1-38	H	N ₃	OH	OH
1-39	H	N ₃	OH	NH ₂
1-40	H	N ₃	OMe	OMe
1-41	H	N ₃	OMe	NH ₂
1-42	H	N ₃	NH ₂	H
1-43	H	N ₃	NH ₂	F
1-44	H	N ₃	NH ₂	Cl
1-45	H	N ₃	NH ₂	Br
1-46	H	N ₃	NH ₂	OH
1-47	H	N ₃	NH ₂	NH ₂
1-48	H	N ₃	NH ₂	OMe
1-49	H	N ₃	H	NHBz
1-50	H	NH ₂	H	NHBz

1-51	H	N ₃	Cl	NHBz
1-52	H	N ₃	OH	NHBz
1-53	H	N ₃	OMe	NHBz
1-54	H	N ₃	NHBz	H
1-55	H	N ₃	NHBz	Cl
1-56	H	N ₃	NHBz	OH
1-57	H	NH ₂	NHBz	OH
1-58	H	N ₃	NHBz	NHBz
1-59	H	N ₃	NHBz	OMe
1-60	Bn	N ₃	H	NHBz
1-61	Bn	N ₃	NHBz	OH
1-62	PMBn	N ₃	H	NHBz
1-63	PMBn	N ₃	NHBz	OH
1-64	MMTr	N ₃	H	NHBz
1-65	MMTr	N ₃	NHBz	OH
1-66	DMTr	N ₃	H	NHBz
1-67	DMTr	N ₃	NHBz	OH
1-68	TMTr	N ₃	H	NHBz
1-69	TMTr	N ₃	NHBz	OH
1-70	TMS	N ₃	H	NHBz
1-71	TMS	N ₃	NHBz	OH
1-72	TBDMS	N ₃	H	NHBz
1-73	TBDMS	N ₃	NHBz	OH
1-74	TBDPS	N ₃	H	NHBz
1-75	TBDPS	N ₃	NHBz	OH

[0031]

Table 2.



(I'')

[0032]

Exemplification Compound number.	R ¹	R ²	R ⁵	R ⁶
2-1	H	NH ₂	H	H
2-2	H	NH ₂	Cl	H
2-3	H	NH ₂	OH	H
2-4	H	NH ₂	OH	Me
2-5	H	NH ₂	SH	H
2-6	H	NH ₂	NH ₂	H
2-7	H	NH ₂	NH ₂	F
2-8	H	NH ₂	NH ₂	Cl
2-9	H	NH ₂	NH ₂	Me
2-10	H	NH ₂	OMe	H
2-11	H	N ₃	H	H
2-12	H	N ₃	Cl	H
2-13	H	N ₃	OH	H
2-14	H	N ₃	OH	Me
2-15	H	N ₃	SH	H
2-16	H	N ₃	NH ₂	H
2-17	H	N ₃	NH ₂	F
2-18	H	N ₃	NH ₂	Cl
2-19	H	N ₃	NH ₂	Me

2-20	H	N ₃	OMe	H
2-21	H	N ₃	NHBz	H
2-22	H	NH ₂	NHBz	H
2-23	H	N ₃	NHBz	F
2-24	H	N ₃	NHBz	Cl
2-25	H	N ₃	NHBz	Me
2-26	Bn	N ₃	OH	H
2-27	Bn	N ₃	OH	Me
2-28	Bn	N ₃	NHBz	H
2-29	PMBn	N ₃	OH	H
2-30	PMBn	N ₃	OH	Me
2-31	PMBn	N ₃	NHBz	H
2-32	MMTr	N ₃	OH	H
2-33	MMTr	N ₃	OH	Me
2-34	MMTr	N ₃	NHBz	H
2-35	DMTr	N ₃	OH	H
2-36	DMTr	N ₃	OH	Me
2-37	DMTr	N ₃	NHBz	H
2-38	TMTr	N ₃	OH	H
2-39	TMTr	N ₃	OH	Me
2-40	TMTr	N ₃	NHBz	H
2-41	TMS	N ₃	OH	H
2-42	TMS	N ₃	OH	Me
2-43	TMS	N ₃	NHBz	H
2-44	TBDMS	N ₃	OH	H
2-45	TBDMS	N ₃	OH	Me
2-46	TBDMS	N ₃	NHBz	H
2-47	TBDPS	N ₃	OH	H
2-48	TBDPS	N ₃	OH	Me
2-49	TBDPS	N ₃	NHBz	H

Among the compounds listed in these Tables, preferred compounds are as follows (Exemplification compound numbers):

1-3, 1-4, 1-7, 1-9, 1-10, 1-16, 1-17, 1-19, 1-20, 1-21, 1-22, 1-23, 1-27, 1-28, 1 to 31, 1 to 33, 1 to 34, 1-40, 1-41, 1-43, 1-44, 1-45, 1-46, 1-47, 1-49, 1-50, 1-56, 1-57, 2-3, 2-4, 2-5, 2-6, 2-7, 2-8, 2-9, 2-10, 2-13, 2-14, 2-15, 2-16, 2-17, 2-18, 2-19, 2-20, 2-21, 2-22, and 2-48.

More preferred compounds are as follows (Exemplification compound numbers):

1-4, 1-22, 1-28, 1-46, 1-49, 1-50, 1-56, 1-57, 2-3, 2-4, 2-6, 2-13, 2-14, 2-16, 2-21, 2-22, and 2-48.

Particularly preferred compounds are as follows (Exemplification compound numbers):

2-4: 3'-amino-3'-deoxy-2'-O,4'-C-methylene-5-methyluridine,

2-14: 3'-azido-3'-deoxy-2'-O,4'-C-methylene-5-methyluridine, and






2-48: 3'-azido-5'-O-tert-butyl-diphenylsilyl-3'-deoxy-2'-O,4'-C-methylene-5-methyluridine

[0033]

[Mode for carrying out the invention]

The compounds of the present invention can be synthesized in accordance with method A described below.

[0034]



In the processes described above, R^1 , R^2 and B are as defined previously.

[0035]

R^7 represents a protecting group for a hydroxy group, and preferred groups are aromatic acyl groups, for example, aryl carbonyl groups such as benzoyl, α -naphthoyl, and β -naphthoyl; lower-alkylated-arylcarbonyl groups such as 2,4,6-trimethylbenzoyl, and 4-toluoyl, and arylated-arylcarbonyl groups such as 4-phenylbenzoyl. The most preferred group is a benzoyl group.

[0036]

R^8 represents a protecting group for a hydroxy group and preferred groups are

"silyl groups", for example, a tri-lower-alkylsilyl group such as trimethylsilyl, triethylsilyl, isopropyldimethylsilyl, t-butyldimethylsilyl, methyldiisopropylsilyl, methyldi-t-butyldimethylsilyl and triisopropylsilyl; and a tri-lower-alkylsilyl group substituted by 1 or 2 aryl groups such as diphenylmethylsilyl, t-butyldiphenylsilyl, diphenylisopropylsilyl and phenyldiisopropylsilyl;

"a methyl group substituted by 1 to 3 aryl groups" such as benzyl, α -naphthylmethyl, β -naphthylmethyl, diphenylmethyl, triphenylmethyl, α -naphthyldiphenylmethyl and 9-anthrylmethyl;

"a methyl group substituted by 1 to 3 aryl groups wherein the aryl ring is substituted by a lower-alkyl, lower-alkoxy, halogen or cyano group" such as 4-methylbenzyl, 2,4,6-trimethylbenzyl, 3,4,5-trimethylbenzyl, 4-methoxybenzyl, 4-methoxyphenyldiphenylmethyl, 4,4'-dimethoxytriphenylmethyl, 4,4',4''-trimethoxytriphenylmethyl, 2-nitrobenzyl, 4-nitrobenzyl, 4-chlorobenzyl, 4-bromobenzyl and 4-cyanobenzyl.

More preferred groups are a trimethylsilyl group, a t-butyldimethylsilyl group, a t-butyldiphenylsilyl group, a benzyl group, a triphenylmethyl group, a 4-methoxybenzyl group, a 4-methoxyphenyldiphenylmethyl group, a 4,4'-dimethoxytriphenylmethyl group or a 4,4',4''-trimethoxytriphenylmethyl group.

[0037]

R⁹ represents a leaving group and preferred groups are a lower-alkylsulfonyl group such as methanesulfonyl and ethanesulfonyl groups, a lower-alkylsulfonyl group substituted by halogen atoms such as trifluoromethanesulfonyl group, and an arylsulfonyl group such as p-toluenesulfonyl group.

Among these groups more preferred groups are methanesulfonyl group or p-toluenesulfonyl group.

[0038]

R¹⁰ represents a protecting group for a hydroxy group and preferred groups are

"Aliphatic acyl groups", for example, alkylcarbonyl groups such as formyl, acetyl, propionyl, butyryl, isobutyryl, pentanoyl, pivaloyl, valeryl, isovaleryl, octanoyl, decanoyl, 1-methylheptadecanoyl, nonadecanoyl, eicosanoyl and heneicosanoyl, carboxylated alkylcarbonyl groups such as succinoyl, glutaroyl and adipoyl groups, halogeno-lower-alkylcarbonyl groups such as chloroacetyl, dichloroacetyl, trichloroacetyl and trifluoroacetyl groups, lower-alkoxy-lower-alkylcarbonyl groups such as a methoxyacetyl group, and unsaturated alkylcarbonyl groups such as a (E)-2-methyl-2-butenoyl group;

"Aromatic acyl groups", for example, arylcarbonyl groups such as benzoyl, α -naphthoyl and β -naphthoyl, halogenoarylcarbonyl groups such as 2-bromobenzoyl and 4-chlorobenzoyl groups, lower-alkylated arylcarbonyl groups such as 2,4,6-trimethylbenzoyl and 4-toluoyl groups, lower-alkoxylated arylcarbonyl groups such as 4-anisoyl group, carboxylated arylcarbonyl groups such as 2-carboxybenzoyl, 3-carboxybenzoyl and 4-carboxybenzoyl groups, nitrated arylcarbonyl groups such as 4-nitrobenzoyl and 2-nitrobenzoyl groups, lower-alkoxycarbonylated arylcarbonyl groups such as 2-(methoxycarbonyl)benzoyl group, and arylated arylcarbonyl groups such as 4-phenylbenzoyl group.

Among these groups, more preferred groups are "aliphatic acyl groups" and a particularly preferred group is an acetyl group.

[0039]

B¹ represents a purine-9-yl or a pyrimidin-1-yl group which may have 1 or more substituents selected from a1 group below.

(a1 group)

a halogen atom,

an alkyl group having from 1 to 6 carbon atoms

a hydroxy group which is optionally protected with a protecting group,

a mercapto group which is optionally protected with a protecting group,

an amino group which is optionally protected with a protecting group,

an alkoxy group having from 1 to 6 carbon atoms,

an alkylthio group having from 1 to 6 carbon atoms, and

a mono- or di-alkylamino group each of which is substituted by alkyl group(s) having from 1 to 6 carbon atoms].

[0040]

Method A is a process to synthesize the compounds of formulae (1a), (1b) and (1c) from the starting compound (2) through introduction of a substituent B and ring closure.

[0041]

Here the starting compound (2) is synthesized from commercially available diacetone-D-glucose using a similar method to that described in the literature (O. T. Schmidt, *Methods in Carbohydr. Chem.*, 4, 318 (1964); J. S. Brimacombe and O. A. Ching, *Carbohydr. Res.*, 8, 82 (1968); T.F. Tam and B. Fraser-Reid, *Can. J. Chem.*, 57, 2818 (1979); S. A. Suzhkov, *Nucleosides & Nucleotides*, 13, 2283 (1994)).

[0042]

Details of each process of method A will be described below.

[0043]

[Method A]

(Process A-1)

A compound (3) is prepared in this step, which comprises deprotection of a primary alcohol protecting group of starting compound (2) in the presence of a base in an inert solvent.

[0044]

The solvent employed has no limitation, insofar as the solvent is one normally used for hydrolysis, and can be water; organic solvents, for example alcohols such as methanol, ethanol and n-propanol, and ethers such as tetrahydrofuran and dioxane; or a mixture of water and the organic solvents described above. Preferred solvents are alcohols.

[0045]

The base employed has no limitation unless it affects other moieties of the compound. Preferred bases are metal alkoxides such as sodium methoxide; alkali metal carbonates such as sodium carbonate, potassium carbonate and lithium carbonate; alkali metal hydroxides such as sodium hydroxide, potassium hydroxide, lithium hydroxide and barium hydroxide, or ammonia such as aqueous ammonia solution and concentrated ammonia-methanol. Preferred bases are alkali metal carbonates.

[0046]

The reaction temperature and reaction time depend upon the starting material, solvent and base employed and have no limitation. Ordinarily the reaction temperature is between 0°C and 15°C and the reaction time is from 1hr to 10 hrs.

[0047]

After termination of the reaction, the desired compound (3) is collected from the reaction mixture by conventional methods. For example, the reaction mixture is neutralized and concentrated, and to the residue is added water and an organic solvent immiscible with water, such as ethyl acetate. After washing with water, the organic phase including the desired compound is isolated, and dried over anhydrous sodium sulfate or the like. The desired compound is obtained by evaporation of the solvents.

[0048]

The compound obtained is, if necessary, purified by conventional methods, such as recrystallization and/or silica gel column chromatography.

[0049]

(Process A-2)

A compound (4) is prepared in this process which comprises reaction of compound (3) obtained in process A-1 with a

hydroxy-protecting agent in the presence of a base in an inert solvent.

[0050]

The solvent employed has no limitation, as far as it does not inhibit the reaction and dissolves the starting materials to some extent and is, for example, an aliphatic hydrocarbon such as hexane and heptane; an aromatic hydrocarbon such as benzene, toluene and xylene; a halogenated hydrocarbon such as methylene chloride, chloroform, carbon tetrachloride, dichloroethane, chlorobenzene and dichlorobenzene; an ester such as ethyl formate, ethyl acetate, propyl acetate, butyl acetate and diethyl carbonate; an ether such as diethyl ether, diisopropyl ether, tetrahydrofuran, dioxane, dimethoxyethane and diethylene glycol dimethyl ether; a nitrile such as acetonitrile and isobutyronitrile; an amide such as formamide, N,N-dimethylformamide, N,N-dimethylacetamide, N-methyl-2-pyrrolidone N-methyl-pyrrolidinone, and hexamethylphosphorotriamide. The preferred solvent is methylene chloride.

[0051]

The base employed has no limitation, as far as it is used as a base in conventional reactions. For example, it can be an organic base such as N-methylmorpholine, triethylamine, tributylamine, diisopropylethylamine, dicyclohexylamine, N-methylpiperidine, pyridine, 4-pyrrolidinopyridine, picoline, 4-(N,N-dimethylamino)pyridine, 2,6-di(tert-butyl)-4-methylpyridine, quinoline, N,N-dimethylaniline and N,N-diethylaniline. The preferred base is triethylamine.

[0052]

The hydroxyl-protecting reagents employed are, for example, silyl halides such as t-butyldimethylsilyl chloride, trimethylsilyl chloride, triethylsilyl chloride, triethylsilyl bromide, triisopropylsilyl chloride, dimethylisopropylsilyl chloride, diethylisopropylsilyl chloride, t-butyldiphenylsilyl chloride, diphenylmethylsilyl chloride, and triphenylsilyl chloride; tritylhalides such as 4-methoxytriphenylmethyl chloride, 4,4'-dimethoxytriphenylmethyl chloride and 4,4',4''-trimethoxytriphenylmethyl chloride; and aralkyl halides such as

benzyl chloride, benzyl bromide and p-methoxybenzyl bromide. The preferred hydroxyl-protecting reagent is t-butyldiphenylsilyl chloride.

[0053]

The reaction temperature is usually between -20° C and the reflux temperature of the solvent employed. The preferred temperature is between 0° C and the reflux temperature of the solvent employed.

[0054]

The reaction time depends upon mainly the reaction temperature, the starting compound, the base and the solvent employed. Ordinarily it is from 10 min to 3 days, and the preferred reaction time is from 1 hr to 24 hrs.

[0055]

After the reaction is terminated, the desired compound (4) in the present reaction is collected from the reaction mixture, according to conventional methods. For example, the reaction mixture is neutralized, and water and an organic solvent immiscible with water, such as ethyl acetate, are added to the neutralized reaction mixture. After washing with water, the organic phase including the desired compound is separated, and dried over anhydrous sodium sulfate or the like. The desired compound is obtained by evaporation of the solvent.

[0056]

The compound obtained is, if necessary, and particularly if a product in which R⁸ is introduced to the hydroxy group at undesired positions is obtained, further purified by conventional methods, such as recrystallization and silica gel column chromatography.

[0057]

(Process A-3)

A compound (5) is prepared in this process which comprises reaction of compound (4) obtained in process A-2 with a leaving-group introducing reagent in the presence of base in an inert solvent.

[0058]

The solvent employed is, for example, an aliphatic hydrocarbon such as hexane, heptane, ligroin and petroleum ether; an aromatic hydrocarbon such as benzene, toluene and xylene; a halogenated

hydrocarbon such as methylene chloride, chloroform, carbon tetrachloride, dichloroethane, chlorobenzene and dichlorobenzene; an ester such as ethyl formate, ethyl acetate, propyl acetate, butyl acetate and diethyl carbonate; an ether such as diethyl ether, diisopropyl ether, tetrahydrofuran, dioxane, dimethoxyethane, and diethylene glycol dimethyl ether; a ketone such as acetone, methyl ethyl ketone and methyl isobutyl ketone, isophorone, and cyclohexanone; a nitro compound such as nitroethane and nitrobenzene; a nitrile such as acetonitrile and isobutyronitrile; an amide such as formamide, N,N-dimethylformamide, N,N-dimethylacetamide, N-methyl-2-pyrrolidone, N-methylpyrrolidinone, and hexamethylphosphorotriamide; a sulfoxide such as sulfolane; or a pyridine.

Among these solvents, the preferred solvent is methylene chloride.

[0059]

Preferred basic catalysts employed are bases such as triethylamine, pyridine and dimethylaminopyridine.

[0060]

The leaving-group introducing reagent employed is, for example, an alkylsulfonyl halide such as methanesulfonyl chloride and ethanesulfonyl bromide; or an arylsulfonyl halide such as p-toluenesulfonyl chloride. Preferred leaving-group introducing reagents are methanesulfonyl chloride and p-toluenesulfonyl chloride.

[0061]

The reaction temperature depends upon the starting compound, solvent, leaving-group introducing reagent and base employed. Usually the temperature is between 0° C and 50° C, and the preferred temperature is between 10° C and 40° C.

[0062]

The reaction time depends upon the starting compound, solvent, leaving-group introducing reagent and base employed. Usually the reaction time is from 10 min to 24 hrs, and the preferred reaction time is from 1 hr to 15 hrs.

[0063]

After termination of the reaction, the desired compound (5)

of this reaction is collected from the reaction mixture according to conventional methods. For example, the reaction mixture is neutralized and concentrated. Water and an organic solvent immiscible with water, such as ethyl acetate, are added to the residue. After washing with water, the organic phase including the desired compound is separated, dried over anhydrous sodium sulfate or the like, and then the desired compound can be obtained by evaporation of the solvents.

[0064]

The compound obtained is, if necessary, purified by conventional methods, such as recrystallization, silica gel column chromatography and the like.

[0065]

(Process A-4)

A compound (6) is prepared in this process which comprises reaction of compound (5) obtained in process A-3 with an acid anhydride in the presence of an acid catalyst in a solvent.

[0066]

The solvent employed is, for example, an ether such as diethylether, dioxane and tetrahydrofuran; a nitrile such as acetonitrile and isobutyronitrile; an amide such as formamide, N,N-dimethylformamide, N,N-dimethyl-acetamide, N-methyl-2-pyrrolidone, N-methylpyrrolidinone and hexamethylphosphorotriamide; or an organic acid such as acetic acid. The preferred solvent is acetic acid.

[0067]

The acid catalyst employed in process A-4 is, for example, an inorganic acid such as hydrochloric acid, sulfuric acid, or nitric acid. The preferred acid is sulfuric acid (particularly concentrated sulfuric acid).

[0068]

The acid anhydride employed is, for example, a lower-aliphatic acid anhydride such as acetic acid anhydride, propionic acid anhydride and the like. The preferred acid anhydride is acetic anhydride.

[0069]

The reaction temperature depends upon the starting compound,

solvent, acid catalyst and acid anhydride employed. Usually the reaction temperature is between 0°C and 50°C, and the preferred reaction temperature is between 10°C and 40°C.

[0070]

The reaction time depends upon the starting compound, solvent, acid catalyst, acid anhydride and the reaction temperature employed. Usually the reaction time is from 10 min to 12 hrs, and the preferred reaction time is from 30 min to 6 hrs.

[0071]

After termination of the reaction, the desired compound (6) of this reaction is collected from the reaction mixture according to conventional methods. For example, water and an organic solvent immiscible with water, such as ethyl acetate, is added to the reaction mixture. After washing with water, the organic phase including the desired compound is isolated, dried over anhydrous sodium sulfate or the like, and then the desired compound can be obtained by evaporation of the solvent.

[0072]

The compound obtained is, if necessary, further purified by conventional methods, such as recrystallization, silica gel column chromatography and the like.

[0073]

(Process A-5)

A compound of (7) is prepared in this process which comprises reaction of compound (6) obtained in process A-4 with a trimethylsilyl derivative of an optionally substituted purine or pyrimidine, which is prepared in accordance with the literature (H. Vorbrueggen, K. Krolikiewicz and B. Bennua, Chem Ber., 114, 1234-1255 (1981)), in the presence of an acid catalyst in an inert solvent.

[0074]

The solvent employed is an aromatic hydrocarbon such as benzene, toluene and xylene; a halogenated hydrocarbon such as methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane, chlorobenzene and dichlorobenzene; a nitrile such as acetonitrile and isobutyronitrile; an amide such as formamide, N,N-dimethylformamide, N,N-dimethylacetamide, N-methyl-2-pyrrolidone,

N-methyl-pyrrolidinone and hexamethylphosphorotriamide; or carbon disulfide. The preferred solvent is 1,2-dichloroethane.

[0075]

The acid catalyst employed is, for example, a Lewis acid catalyst such as AlCl_3 , SnCl_4 , TiCl_4 , ZnCl_2 , BF_3 and trimethylsilyl trifluoromethanesulfonate. The preferred acid catalyst is tin tetrachloride (SnCl_4).

[0076]

The reaction temperature depends upon the starting compound, solvent and acid catalyst employed. Usually the reaction temperature is between 0°C and 100°C , and the preferred reaction temperature is between 30°C and 80°C .

[0077]

The reaction time depends upon the starting compound, solvent, acid catalyst, and reaction temperature employed. Usually the reaction time is from 1 hr to 3 days, and the preferred reaction time is from 1 hr to 2 days.

[0078]

After termination of the reaction, the desired compound (7) of this reaction is collected from the reaction mixture according to conventional methods. For example, the reaction mixture is neutralized, and water and an organic solvent immiscible with water, such as ethyl acetate or methylene chloride, is added to the resulting mixture. After washing with water, the organic phase including the desired compound is separated, dried over anhydrous sodium sulfate or the like, and then the desired compound can be obtained by evaporation of the solvent.

[0079]

The compound obtained is, if necessary, purified by conventional methods, for example recrystallization, silica gel column chromatography, and the like.

[0080]

(Process A-6)

A compound (1a) is prepared in this process which comprises a cyclization reaction of compound (7) obtained in process A-5 in the presence of a basic catalyst in an inert solvent.

[0081]

The solvent employed has no limitation as far as it does not inhibit the reaction and it dissolves the starting compound to some extent. Preferred solvents are alcohols such as methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, t-butanol, isoamyl alcohol, diethylene glycol, glycerin, octanol, cyclohexanol and methyl cellosolve. The most preferred solvent is methanol.

[0082]

The basic catalyst employed is, for example, an alkali metal hydroxide such as sodium hydroxide and potassium hydroxide; an alkali metal carbonate such as sodium carbonate and potassium carbonate; an alkali metal alkoxide such as sodium methoxide and sodium ethoxide; or aqueous ammonia solution and the like. Preferred basic catalysts are alkaline metal carbonates and the most preferred basic catalyst is sodium carbonate.

[0083]

The reaction temperature depends upon the starting compound, solvent, and basic catalyst employed. Usually the reaction temperature is between 0° C and 50° C, and the preferred reaction temperature is between 10° C and 30° C.

[0084]

The reaction time depends upon the starting compound, solvent, basic catalyst, and the reaction temperature employed. Usually the reaction time is from 1 hr to 3 days, and the preferred reaction time is from 3 hr to 2 days.

[0085]

After termination of the reaction, the desired compound (1a) of this reaction is collected from the reaction mixture according to conventional methods. For example, the reaction mixture is concentrated, and water and an organic solvent immiscible with water, such as ethyl acetate, are added to the residue. After washing with water, the organic phase including the desired compound is separated, dried over anhydrous sodium sulfate or the like, and then the desired compound can be obtained by evaporation of the solvent.

[0086]

The compound obtained is, if necessary, purified by

conventional methods, for example, recrystallization, silica gel column chromatography, and the like.

[0087]

(Process A-7)

A compound (1b) is prepared in this process which comprises reaction of compound (1a) obtained in process A-6 with a deprotecting agent in an inert solvent. In the case that deprotection is unnecessary, the next process can be conducted without this process.

[0088]

The process of deprotection depends upon the protecting groups employed, and the deprotecting reagent has no limitation unless it has an adverse effect on the reaction. For instance, the deprotection can be carried out according to methods described in the literature of "Protective Groups in Organic Synthesis" (Theodora W. Greene, 1981, A Wiley-Interscience Publication).

When different kinds of protecting groups exist, some of these methods are appropriately combined and each of these carried out in turn.

[0089]

Particularly when the protecting groups are (1) "aliphatic acyl or aromatic acyl groups", (2) "a methyl group substituted by 1 to 3 aryl groups" or a "methyl groups substituted by 1 to 3 aryl rings wherein the aryl ring is substituted by lower-alkyl, lower-alkoxy, cyano group or halogen atom", (3) "silyl groups", the protecting groups can be deprotected with the following methods.

[0090]

(1) When the protecting groups are aliphatic acyl or aromatic acyl groups, they are usually deprotected by reaction with bases in inert solvents.

[0091]

The solvents employed have no limitation as far as they are usually used in hydrolysis. For instance, water; organic solvents, for example, alcohols such as methanol, ethanol, and n-propanol; ethers such as tetrahydrofuran and dioxane, or a mixture of water and above organic solvents are used. The preferred solvents are alcohols.

[0092]

The bases employed have no limitation unless they affect other moieties of the compounds. Preferred bases are metal alkoxides such as sodium methoxide; alkali metal carbonates such as sodium carbonate, potassium carbonate and lithium carbonate; alkali metal hydroxides such as sodium hydroxide, potassium hydroxide, lithium hydroxide and barium hydroxide; or ammonia such as aqueous ammonia solutions and concentrated ammonium-ethanol. Preferred bases are alkali metal carbonates.

[0093]

The reaction temperature and the reaction time depend upon the starting compound, solvent, base employed. Usually the reaction temperature is between 0°C and 150°C and the reaction time is from 1 hr. to 10 hrs. in order to suppress production of by-products.

[0094]

After termination of the reaction, the desired compound (1b) of this reaction is collected from the reaction mixture according to conventional methods. For example, the reaction mixture is concentrated, and water and an organic solvent immiscible with water, such as ethyl acetate, are added to the residue. After washing with water, the organic phase including the desired compound is separated, dried over anhydrous sodium sulfate or the like, and then the desired compound can be obtained by evaporation of the solvent.

The compound obtained is, if necessary, purified by conventional methods, for example recrystallization, silica gel column chromatography and the like.

[0095]

(2) In the case that the protecting group is "a methyl group substituted by 1 to 3 aryl groups" or "a methyl group substituted by 1 to 3 aryl groups wherein aryl ring is substituted by lower-alkyl, lower-alkoxy group, halogen atom or a cyano group", deprotection is carried out by a reducing reagent in an inert solvent.

[0096]

Preferred solvents employed are alcohols such as methanol, ethanol and isopropanol; ethers such as diethyl ether, tetrahydrofuran and dioxane; aromatic hydrocarbons such as toluene,

benzene and xylene; aliphatic hydrocarbons such as hexane and cyclohexane; esters such as ethyl acetate and propyl acetate; organic acids such as acetic acid; or mixtures of these organic solvents and water.

[0097]

The reducing reagents employed have no limitation if they are usually used in catalytic reactions. Preferred reducing agents are palladium-carbon, Raney nickel, platinum oxide, platinum black, rhodium-aluminium oxide, triphenylphosphine-rhodium chloride and palladium-barium sulfate.

[0098]

The reaction pressure has no limitation. Usually this process is performed under 1 to 10 atmosphere.

[0099]

The reaction temperature is between 0°C and 60°C, and the preferred reaction temperature is between 20°C and 40°C.

[0100]

The reaction time is from 10 min. to 24 hrs. and the preferred reaction time is from 1 to 3 hrs.

[0101]

After termination of the reaction, the desired compound (1b) of this reaction is collected from the reaction mixture according to conventional methods. For example, the reducing reagent is removed, and water and an organic solvent immiscible with water, such as ethyl acetate, are added to the reaction mixture. After washing with water, the organic phase including the desired compound is separated, dried over anhydrous sodium sulfate or the like, and then the desired compound can be obtained by evaporation of the solvent.

[0102]

The compound obtained is, if necessary, further purified by conventional methods, for example recrystallization, silica gel column chromatography and the like.

[0103]

When the protecting group is "a methyl group substituted by 3 aryl groups", *i.e.*, when the protecting group is a trityl group, deprotection can also be carried out using an acid.

[0104]

In this case, the following solvents are used, for example, aromatic hydrocarbons such as benzene, toluene and xylene; halogenated hydrocarbons such as methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane, chlorobenzene and dichlorobenzene; alcohols such as methanol, ethanol, isopropanol and tert-butanol; nitriles such as acetonitrile and isobutyronitrile; amides such as formamide, N,N-dimethyl formamide, N,N-dimethylacetamide, N-methyl-2-pyrrolidone, N-methyl-pyrrolidinone, and hexamethylphosphorotriamide; and organic acids such as acetic acid. Preferred solvents are organic acids (particularly acetic acid) and alcohols (particularly tert-butanol).

[0105]

The preferred acid to use is acetic acid or trifluoroacetic acid.

[0106]

The reaction temperature is between 0°C and 60°C, and the preferred reaction temperature is between 20°C and 40°C.

[0107]

The reaction time is from 10 min to 24 hrs and the preferred reaction time is from 1 to 3 hrs.

[0108]

After termination of the reaction, the desired compound (1b) of this reaction is collected from the reaction mixture according to conventional methods. For example, the reaction mixture is neutralized, and water and an organic solvent immiscible with water, such as ethyl acetate, are added to the resulting mixture. After washing with water, the organic phase including the desired compound is separated, dried over anhydrous sodium sulfate or the like, and then the desired compound can be obtained by evaporation of the solvent.

The compound obtained is, if necessary, further purified by conventional methods, for example recrystallization, silica gel column chromatography and the like.

[0109]

(3) In the case that the protecting group is "a silyl group",

the protecting group is usually deprotected by treatment with compounds which produce fluorine anion, such as tetrabutylammonium fluoride, hydrofluoric acid, hydrofluoric acid-pyridine, and potassium fluoride, or organic acids such as acetic acid, methanesulfonic acid, para-toluenesulfonic acid, trifluoroacetic acid, and trifluoromethanesulfonic acid, or inorganic acids such as hydrochloric acid.

[0110]

When the protecting group is deprotected with fluorine anion, the reaction is, in some cases, accelerated by addition of an organic acid such as formic acid, acetic acid or propionic acid.

[0111]

The solvents used have no limitation as far as they do not inhibit the reaction and they dissolve the starting materials to some extent. However, preferred solvents are ethers such as diethyl ether, diisopropylether, tetrahydrofuran, dioxane, dimethoxyethane and diethylene glycol dimethylether; nitriles such as acetonitrile and isobutyronitrile; water; organic acids such as acetic acid, and mixtures of these solvents described above.

[0112]

The reaction temperature is between 0°C and 100°C, and the preferred reaction temperature is between 20°C to 70°C.

[0113]

The reaction time is from 5 min. to 48 hrs. and the preferred reaction time is from 1 to 24 hrs.

[0114]

After termination of the reaction, the desired compound (1b) of this reaction is collected from the reaction mixture according to conventional methods. For example, the solvents are evaporated and then the compound is purified by silica gel column chromatography.

[0115]

(Process A-8)

A compound (1c) is prepared in this process which comprises catalytic reduction of the azido group in compound (1b) obtained in process A-7 to an amino group in the presence of hydrogen and a catalyst in an inert solvent and, if necessary, protection of

the amino group.

[0116]

The solvents employed have no limitation as far as they do not have an adverse effect on this reaction. Preferred solvents are alcohols such as methanol, ethanol and isopropanol; ethers such as diethylether, tetrahydrofuran and dioxane; aromatic hydrocarbons such as toluene, benzene and xylene; aliphatic hydrocarbons such as hexane and cyclohexane; esters such as ethyl acetate and propyl acetate; amides such as formamide, dimethylformamide, dimethylacetamide, N-methyl-2-pyrrolidone and hexamethylphosphorotriamide; aliphatic acids such as formic acid and acetic acid; water; or mixtures of these solvents described above.

[0117]

The catalysts employed have no limitation if they are usually used in catalytic reductions. Preferred catalysts are palladium on carbon, palladium black, Raney nickel, platinum oxide, platinum black, rhodium-aluminium oxide, triphenylphosphine-rhodium chloride, palladium-barium sulfate.

[0118]

The reaction pressure has no limitation, but is usually between 1 and 10 atmospheres.

[0119]

The reaction temperature and reaction time depends upon the starting compound, solvent, and catalyst employed. Usually the reaction temperature is between 0° C and 100° C (preferred reaction temperature is between 20° C and 40° C), and the reaction time is from 5 min. to 48 hrs. (preferred reaction time is from 30 min. to 10 hrs.).

[0120]

After termination of the reaction, the desired compound (1c) of this reaction is collected from the reaction mixture according to conventional methods. For example, the desired compound can be obtained through removal of the catalysts by filtration and by evaporation of solvent from the filtrate.

[0121]

If desired, the amino group can be protected in accordance with



the methods described in the above literature (Protective Groups in Organic Synthesis).

[0122]

A N3'-P5' type oligonucleotide analogue of this invention in which the nitrogen atom at 3' position and the oxygen atom at 5' position are combined through phosphoric acid can be prepared using compound (1d) of this invention according to method B described below.

[0123]

Method B



In the processes described above, B¹ and R⁸ are as defined previously. However B¹ in the formula (1d) and B¹ in the formula (8) may be the same or different.

[0124]

R¹¹ represents a resin such as succinyl Controlled Pore Glass or Tentagel, which is usually employed for the synthesis of oligonucleotides.

CEO represents a 2-cyanoethoxy group.

[0125]

Each process of method B will be described below in detail.

[0126]

(Process B-1)

A compound (9) is prepared in this process which comprises an oxidative phosphorylation coupling reaction of compound (1d) with compound (8). This process is performed as described in the literature (1) (Nucleic Acids Research, Vol. 23, No. 14, pp. 2661-2668, 1995).

[0127]

The hydroxy group at the 5' position of the compound (1d) is protected in compound (1c) in Process A-8, and if an amino group exists in the base B, said amino group of compound (1d) is protected.

Further, the compound (8) can be prepared from the compound (1c) obtained in "Process A-8", in accordance with the literature (1).

[0128]

(Process B-2)

This process is to produce an oligonucleotide from compound (9) obtained in the "Process B-1".

[0129]

The process comprises deprotection of the hydroxyl-protecting group R⁸ of compound (9) by a procedure of process A-7, phosphorylation in accordance with the literature (1), reaction with compound (1d) in a method similar to that described in the Process B-1, followed by repetition of these reactions to give the desired oligonucleotide.

[0130]

The sequence length of oligonucleotides containing non-natural modified nucleoside obtained is usually 2-50 nucleoside units, and the preferred length is 10-30 nucleoside units.

[0131]

The oligonucleotide containing non-natural modified nucleoside obtained are resistant to various nucleases. Thus they remain in the body for a long time after administration. Further, the oligonucleotide analogues, for instance, form stable double

strands with mRNA, and inhibit biosynthesis of proteins which contribute to pathogenesis, or inhibit transcription to mRNA by forming triplets with the DNA double strands in genomes, or inhibit proliferation of viruses.

[0132]

Thus the oligonucleotides containing these non-natural modified nucleoside can suppress specified genome functions, and are expected to be therapeutic agents used for the treatment of diseases, such as anti-neoplasm agents, anti-viral agents, or the like.

[0133]

Non-oral formulations or liposome formulations of the oligonucleotides containing non-natural modified nucleoside of this invention can be prepared, for instance, by addition of conventional adjuvants such as buffers and/or stabilizers. The nucleotide analogues may be blended with conventional pharmaceutical carriers to prepare ointments, creams, liquids or plasters.

[0134]

The hybrid forming activity and tolerance to nucleases of the oligonucleotides containing non-natural modified nucleoside of the present invention were able to be determined by using the following methods.

[0135]

(Test method 1)

The melting temperatures (T_m values) of the annealing products between antisense strands, which are the various non-natural modified oligonucleotide analogues obtained, and natural DNA- or RNA-based sense strands are measured to investigate the hybridizing ability of the oligonucleotide analogues of the present invention for complementary DNA and RNA.

[0136]

Each sample solution (500 μ l) with final concentrations of 100 mM sodium chloride, 10 mM sodium phosphate buffer (pH 7.2), 4 μ M antisense strand, and 4 μ M sense strand, respectively, is heated in a boiling water bath, and slowly cooled to room temperature over

10 hours. The sample solution in a cell chamber of a spectrophotometer (UV-2100PC, manufactured by Shimadzu Cor.,) is gradually cooled to 5° C, kept at 5° C for a further period of 20 minutes, and then the measurement is started, in a stream of nitrogen gas in order to prevent condensation of moisture. The sample temperature is raised at a rate of 0.2° C/minute until 90° C, and the ultraviolet absorption at 260 nm is measured at intervals of 0.1° C.

[0137]

In order to prevent changes of the sample concentration with increases in the temperature, a cell with a cover is used, and a drop of a mineral oil is applied on the surface of the sample solution during measurement.

[0138]

(Test example 2)

(Determination of tolerance to nucleases)

A buffer solution of snake venom phosphodiesterase (0.003U/ml, 400 µl) is added to a buffer of a oligonucleotide (10 µl, 400 µl) kept at 37°C and the mixture is stirred for 15 minutes. The resulting mixture is put into a quartz cell (800 µl). The time course of increase of absorption at 260 nm of ultra violet is measured on SHIMADZU UV-2100PC. The buffer comprises Tris-HCl (pH 8.6), NaCl 0.1M, and MgCl₂ 14 mM and is sufficiently deaerated .

[0139]

Half-life time is determined using the time at which UV absorption value shows the average UV absorption from the start (t=0) of the measurement to the disappearance of UV absorption. The half-life times of the compound of the present invention are compared to those of natural oligonucleotides.

[0140]

(Test method 3)

Determination of anti-HIV activity

Anti-HIV activities of the oligonucleotide analogues of the present invention are determined by a similar method to that described by R. Pauwel et al. (J. Virological Method, 20, p. 309-321 (1988)). The cell precipitate is suspended in RPMI-1640 medium which does

not contain serum. To the suspension is added HIV and the mixture is incubated at 37°C for 1 hour. At the end of this time the resulting mixture is washed with RPMI-1640 medium containing 10% fetal bovine serum (hereinafter called "serum medium") and centrifuged (1000 x g, 5 min). The HIV infected cell thus obtained and HIV non-infected cells are suspended in the serum medium so as to have a concentration of 4×10^5 /ml, respectively. After 100 μ l of the suspension is placed in each well of a 96-well plate for tissue culture, they are incubated for 5 days at 37°C in the presence of carbon dioxide gas without stirring. HIV infected cells and non-infected cells without test compounds are similarly incubated. After the incubation, the living cells are counted by using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) and cell injury inhibitory activities of test compounds are determined. It is confirmed that Mycoplasma is not contained in the cell solution and virus solution incubated.

[0141]

Inhibitory activity of cell injury in HIV non-infected cells without a test compound is expressed as 100%, and inhibitory activity of cell injury in HIV infected cells without a test compound is expressed as 0%. The concentration of the compound to inhibit cell injury by 50% (EC_{50}) is determined.

[0142]

The present invention will be described below in more detail by way of the following Examples and Reference examples. However, the present invention is not limited to those examples.

[0143]

[Examples]

[0144]

(Example 1)

3'-Azido-5'-O-tert-butyldiphenylsilyl-3'-deoxy-2'-O,4'-C-methylene-5-methyluridine (Exemplification compound number 2-48)
Potassium carbonate (41 mg, 0.29 mmol) was added to a methanol solution (7 ml) of the compound obtained in Reference example 5 (200 mg, 0.27 mmol) at 0°C and the mixture was stirred for 4.5 hrs at room temperature. Further potassium carbonate (34 mg, 0.25 mmol)

was added to the mixture, which was stirred for 23 hrs. After the methanol was evaporated, the residue was partitioned between ethyl acetate and water. The extract was washed with saturated aqueous sodium chloride solution. The organic phase was dried over anhydrous sodium sulfate. The solvents were evaporated and the residue was purified by silica gel column chromatography (ethyl acetate: n-hexane = 2:1) to give the title compound as colorless crystals (142 mg, 0.27 mmol, 100%).

mp 93-95° C.

IR ν_{max} (KBr): 3169, 3047, 2956, 2888, 2859, 2117, 1696, 1275, 1109 cm^{-1} .

$^1\text{H-NMR}$ (CDCl_3) δ : 1.12 (9H, s), 1.65 (3H, s), 3.78, 3.84 (2H, AB, $J = 8$ Hz), 3.90, 4.08 (2H, AB, $J = 12.5$ Hz), 4.02 (1H, s), 4.67 (1H, s), 5.67 (1H, s), 7.54 (1H, s), 7.39-7.48 (6H, m), 7.67-7.71 (4H, m), 8.46 (1H, br s).

$^{13}\text{C-NMR}$ (CDCl_3) δ : 12.3, 19.5, 27.0, 58.7, 60.3, 71.4, 77.2, 78.6, 87.2, 90.1, 110.8, 128.0, 130.1, 130.2, 131.7, 132.3, 133.7, 135.1, 135.4, 149.6, 163.6.

[0145]

(Example 2)

3'-Azido-3'-deoxy-2'-O.4'-C-methylene-5-methyluridine

(Exemplification compound number 2-14)

Tetrabutylammonium fluoride (10 M in THF, 290 μl , 0.29 mmol) was added to an anhydrous tetrahydrofuran solution (5 ml) of the compound obtained in Example 1 (140 mg, 0.26 mmol) in a stream of nitrogen gas and the solution was stirred for 1 hr at room temperature. The solvent was evaporated and the residue was purified by silica gel column chromatography (ethyl acetate: n-hexane = 25:1) and the title compound was obtained as a white powder (65.7 mg, 0.22 mmol, 85%).

mp 94-96° C.

IR ν_{max} (KBr): 3163, 3046, 2118, 1692, 1468, 1273, 1062 cm^{-1} .

$^1\text{H-NMR}$ (CD_3OD) δ : 1.89 (3H, s), 3.76, 3.86 (2H, AB, $J = 8$ Hz), 3.85, 3.95 (2H, AB, $J = 13$ Hz), 4.03 (1H, s), 4.58 (1H, s), 5.58 (1H, s), 7.70 (1H, s).

^{13}C -NMR (CD_3OD) δ : 12.8, 57.3, 61.2, 72.4, 79.8, 88.3, 91.0, 110.8, 136.3, 151.5, 166.1.

[0146]

(Example 3)

3'-Amino-3'-deoxy-2'-O-4'-C-methylene-5-methyluridine

(Exemplification compound number 2-4)

An ethanol solution (3 ml) of the compound obtained in Example 2 (64 mg, 0.22 mmol) was added to 10% palladium-carbon (28 mg) suspended in anhydrous tetrahydrofuran solution (5 ml) in a stream of hydrogen gas, and the mixture was stirred for 0.5 hr at room temperature. The reaction mixture was filtered and the solvent of the filtrate was evaporated and the title compound was obtained as a white powder (59 mg, 0.22 mmol, 100%).

mp 243-246°C.

IR ν_{max} (KBr): 3459, 3365, 1699, 1447, 1273, 1054 cm^{-1} .

^1H -NMR ($\text{C}_5\text{D}_5\text{N}$) δ : 1.83 (3H, s), 3.62 (1H, s), 3.92, 4.14 (2H, AB, $J = 8$ Hz), 4.24 (2H, s), 4.54 (1H, s), 5.97 (1H, s), 7.90 (1H, s).

^{13}C -NMR ($\text{C}_5\text{D}_5\text{N}$) δ : 12.8, 54.2, 57.2, 71.6, 81.4, 91.1, 109.5, 150.8, 164.3.

[0147]

[Reference example]

[0148]

(Reference Example 1)

3-Azido-3-deoxy-4-hydroxymethyl-1,2-O-isopropylidene- α -D-ribofuranose

Potassium carbonate (380 mg, 2.75 mmol) and water (15 ml) were added to a methanol solution (85 ml) of 3-azido-4-benzoyloxymethyl-5-O-benzoyl-3-deoxy-1,2-O-isopropylidene- α -D-ribofuranose (4.13 g, 9.15 mmol) prepared in accordance with the literature (Surzhykov S.A., Krayevsky A.A., Nucleosides Nucleotides, 13, 2283-2305 (1994)) at 0°C, and the mixture was stirred for 4.5 hrs at 0°C. Then the reaction mixture was neutralized with 10% hydrochloric acid solution at 0°C, and the methanol was evaporated. Water was added to the residue, then, after extraction with ethyl acetate, the extracts were washed with saturated aqueous sodium chloride

solution. The organic phase was dried over anhydrous sodium sulfate. The solvent was evaporated. The white solid obtained was washed with cold n-hexane and the desired compound was obtained as a white powder (1.93 g, 7.87 mmol, 86%).

mp 113-115°C (toluene).

IR ν_{max} (KBr): 3460, 3417, 2989, 2951, 2907, 2111 cm^{-1} .

$^1\text{H-NMR}$ (CDCl_3) δ : 1.62 (3H, s), 1.35 (3H, s), 2.65 (2H, br s), 3.81, 3.65 (2H, AB, $J = 12$ Hz), 3.59, 4.00 (2H, AB, $J = 12.5$ Hz), 4.28 (1H, d, $J = 5.5$ Hz), 4.82 (1H, dd, $J = 4$ Hz, 5.5 Hz), 5.85 (1H, d, $J = 4$ Hz).

$^{13}\text{C-NMR}$ (CDCl_3) δ : 25.7, 26.2, 61.9, 62.1, 63.2, 79.9, 87.3, 104.4, 113.6.

[0149]

(Reference Example 2)

3-Azido-5-O-tert-butyldiphenylsilyl-3-deoxy-4-hydroxydimethyl-1,2-O-isopropylidene- α -D-ribofuranose

Triethylamine (3.5 g, 4.82 ml, 34.6 mmol) and t-butyldiphenylsilyl chloride (9.75 g, 9.22 ml, 35.46 mmol) were added to an anhydrous methylene chloride solution (73 ml) of the compound obtained in Reference Example 1 (2.56 mg, 10.5 mmol) and the solution was stirred for 24 hrs at room temperature. Then saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, and the resulting mixture was extracted with ethyl acetate and the extracts washed with saturated aqueous sodium chloride solution. The organic phase was dried over anhydrous sodium sulfate. After the solvent was evaporated, the residue was purified by silica gel column chromatography (ethyl acetate: n-hexane = 1:6). The desired compound was obtained as a white powder (3.13 g, 6.47 mmol, 62%). mp 99.5-100.5°C (n-hexane).

IR ν_{max} (KBr): 3504, 2936, 2852, 2111 cm^{-1} .

$^1\text{H-NMR}$ (CDCl_3) δ : 1.07 (9H, s), 1.36 (3H, s), 1.62 (3H, s), 3.62, 3.92 (2H, AB, $J = 12$ Hz), 4.38 (1H, d, $J = 6$ Hz), 4.84 (1H, dd, $J = 4$ Hz, 5.5 Hz), 3.82, 3.70 (2H, AB, $J = 11$ Hz), 4.84 (1H, dd, $J = 4$ Hz, 5.5 Hz), 5.86 (1H, d, $J = 4$ Hz), 7.36-7.44 (6H, m), 7.64-7.67 (4H, m).

^{13}C -NMR (CDCl_3) δ : 19.2, 26.1, 26.3, 26.8, 62.2, 62.3, 65.2, 80.4, 88.0, 104.5, 113.7, 127.7, 127.8, 129.8, 129.9, 132.7, 132.8, 135.5.
[0150]

(Reference Example 3)

3-Azido-5-O-tert-butyl-diphenylsilyl-3-deoxy-4-(p-toluenesulfonyloxymethyl)-1,2-O-isopropylidene- α -D-ribofuranose

Triethylamine (137 mg, 180 μl , 1.29 mmol), p-toluenesulfonyl chloride (63.3 mg, 0.33 mmol) and 4-dimethylaminopyridine (4 mg, 0.03 mmol) were added to an anhydrous methylene chloride solution (2 ml) of the compound obtained in Reference Example 2 (100 mg, 0.21 mmol) at 0°C in a stream of nitrogen gas, and the solution was stirred for 14 hrs at room temperature. Then saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, the resulting mixture was extracted with ethyl acetate and the extracts washed with saturated sodium chloride solution. The organic phase was dried over anhydrous sodium sulfate. After the solvent was evaporated, the residue was purified by silica gel column chromatography (ethyl acetate: n-hexane = 1:6). The desired compound was obtained as a white powder (130 mg, 0.20 mmol, 98%). mp 122-124°C (ethyl acetate-n-hexane).

IR ν_{max} (KBr): 3069, 2935, 2114, 1366, 1183, 1109 cm^{-1} .

^1H -NMR (CDCl_3) δ : 1.03 (9H, s), 1.27 (3H, s), 1.31 (3H, s), 2.41 (3H, s), 3.60, 3.72 (2H, AB, J = 10.5 Hz), 4.33, 4.40 (2H, AB, J = 10 Hz), 4.55 (1H, d, J = 5.5 Hz), 5.00 (1H, dd, J = 3.7 Hz, 5.5 Hz), 5.82 (1H, d, J = 3.7 Hz), 7.23 (2H, d, J = 8.5 Hz), 7.36-7.45 (6H, m), 7.61-7.63 (4H, m), 7.72 (2H, d, J = 8.5 Hz).

^{13}C -NMR (CDCl_3) δ : 19.1, 21.5, 25.9, 26.0, 26.7, 63.1, 64.7, 68.9, 80.1, 85.6, 104.4, 113.8, 127.8, 128.0, 129.6, 129.9, 132.4, 132.5, 135.4, 144.6.

[0151]

(Reference Example 4)

3-Azido-5-O-tert-butyl-diphenylsilyl-3-deoxy-4-(p-toluenesulfonyloxymethyl)-1,2-di-O-acetyl-D-ribofuranose

Acetic anhydride (406 mg, 375 μl , 3.98 mmol) and concentrated

sulfuric acid (6.5 mg, 3.5 μ l, 0.066 mmol) were added to an acetic acid solution (3.5 ml) of the compound obtained in Reference Example 3 (230 mg, 0.36 mmol) in a stream of nitrogen gas and the solution was stirred for 5 hrs at room temperature. Then ice-water was added to the reaction mixture, and after stirring for 30 min, saturated aqueous sodium chloride solution was added. The resulting mixture was extracted with ethyl acetate. The organic phase was dried over anhydrous sodium sulfate. After the solvent was evaporated, the residue was purified by silica gel column chromatography (ethyl acetate: n-hexane = 4:1). The desired compound, which is a mixture of α : β = approximately 3:7, was obtained as a colorless oil (230 mg, 0.34 mmol, 94%).

IR ν_{\max} (KBr): 3048, 2935, 2864, 2117, 1756. cm^{-1} .

$^1\text{H-NMR}$ (CDCl_3) [β form] δ : 1.06 (9H, s), 1.83 (3H, s), 2.08 (3H, s), 2.40 (3H, s), 3.54, 3.80 (2H, AB, J = 11 Hz), 4.12, 4.26 (2H, AB, J = 10 Hz), 4.37 (1H, d, J = 5.5 Hz), 5.32 (1H, d, J = 5.5 Hz), 5.98 (1H, s), 7.29 (2H, d, J = 8 Hz), 7.37-7.46 (6H, m), 7.59-7.65 (4H, m), 7.76 (2H, d, J = 8 Hz).

[α form] δ : 1.05 (9H, s), 2.02 (3H, s), 2.13 (3H, s), 2.39 (3H, s), 3.51, 3.68 (2H, AB, J = 11 Hz), 4.12, 4.21 (2H, AB, J = 10.5 Hz), 4.40 (1H, d, J = 7 Hz), 5.32 (1H, m), 6.31 (1H, d, J = 4.5 Hz), 7.25 (2H, d, J = 8.5 Hz), 7.37-7.46 (6H, m), 7.59-7.65 (4H, m), 7.70 (2H, d, J = 8.5 Hz).

$^{13}\text{C-NMR}$ (CDCl_3) δ : 19.0, 19.1, 20.0, 20.6, 20.9, 21.1, 21.5, 26.6, 61.0, 63.2, 65.1, 68.4, 68.8, 72.2, 75.5, 85.4, 86.5, 93.6, 96.0, 97.3, 127.8, 127.9, 128.0, 129.6, 129.9, 130.0, 132.0, 132.3, 132.4, 135.4, 144.7, 168.5, 169.2, 169.3, 169.4.

[0152]

(Reference Example 5)

2'-O-Acetyl-3'-azido-5'-O-tert-butyldiphenylsilyl-3'-deoxy-4'-(p-toluenesulfonyloxymethyl)-5-methyluridine

O,O'-Bis(trimethylsilyl)thymine (240 mg, 0.93 mmol) and tin tetrachloride (253 mg, 114 μ l, 0.97 mmol) were added to an anhydrous 1,2-dichloroethane solution (6 ml) of the compound obtained in Reference Example 4 (300 mg, 0.44 mmol) at 0°C in a stream of nitrogen

gas, and the solution was stirred for 43 hrs at room temperature. After the reaction mixture was diluted with dichloromethane in an ice bath, saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, which was then extracted with dichloromethane. The extracts were washed with saturated aqueous sodium chloride solution. After the organic phase was dried over anhydrous sodium sulfate, the solvent was evaporated and the residue was purified by silica gel column chromatography (ethyl acetate: n-hexane = 1:2-1:0). The desired compound was obtained as a white powder (300 mg, 0.4 mmol, 91%).

mp 158.5-159.5°C (ethyl acetate-n-hexane).

$^1\text{H-NMR}$ (CDCl_3) δ : 1.11 (9H, s), 1.59 (3H, s), 2.15 (3H, s), 2.41 (3H, s), 3.80, 3.84 (2H, AB, $J = 11.5$ Hz), 4.04, 4.10 (2H, AB, $J = 11$ Hz), 4.47 (1H, d, $J = 6$ Hz), 5.53 (1H, t, $J = 6.5$ Hz), 5.94 (1H, d, $J = 7$ Hz), 7.18 (1H, s), 7.28 (2H, d, $J = 7.5$ Hz), 7.37-7.47 (6H, m), 7.61-7.65 (4H, m), 7.71 (2H, d, $J = 7.5$ Hz), 9.68 (1H, br s).

$^{13}\text{C-NMR}$ (CDCl_3) δ : 11.8, 19.2, 20.9, 21.5, 26.9, 62.3, 65.9, 68.3, 74.2, 84.8, 86.1, 118.9, 127.9, 128.0, 129.7, 130.1, 131.5, 132.2, 135.2, 135.3, 135.5, 145.0, 150.4, 163.6, 169.9.

[0153]

[Advantages of the invention]

Novel bicyclonucleoside analogues of the present invention are useful as anti-AIDS agents and are useful as intermediates for producing non-natural modified oligonucleotide analogues which exhibit excellent anti-sense or anti-gene activities and in vivo stability.

[Document name] Abstract


[Abstract]

[Subject]

This invention provides novel modified nucleoside analogues which exhibit anti-AIDS activity and intermediates to produce non-natural modified oligonucleotide analogues which have anti-sense or anti-gene activity as well as in vivo stability.

[Solution]

The present invention relates to a compound of the following formula (1) or pharmaceutically acceptable salt thereof.



(1)

R¹ is the same or different and each represents a hydrogen atom or a protecting group for a hydroxy group,

R² represents an azido group or an amino group which is optionally protected with a protecting group,

B represents a purin-9-yl or a pyrimidin-1-yl group each of which is optionally substituted with substituents selected from α group shown below.

(α group)

a halogen atom, an alkyl group having from 1 to 6 carbon atoms, a hydroxy group, a mercapto group, an amino group, and the like.

[Selected figure] None